{"DataElement":{"publicId":"2442630","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Result Score","preferredDefinition":"the source of an Oncotype DX breast cancer assay, a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100).","longName":"LAB_ONCODX_RSL_SC","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2442628","version":"1","preferredName":"Laboratory Procedure Oncotype DX Breast Cancer Assay Result","preferredDefinition":"information related the result of the medical procedure that involves testing a tissue sample by Oncotype DX breast cancer assay, a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100).","longName":"LAB_ONCOTPDX_RSLT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2738969","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Result","preferredDefinition":"Oncotype DX is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen. (from genomichealth.com):Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C52159:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncotype DX Breast Cancer Assay","conceptCode":"C52159","definition":"A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A0BAA4E-2013-0049-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-04","modifiedBy":"ONEDATA","dateModified":"2008-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-51D9-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-01-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"**Laboratory Clean-Up**","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2442629","version":"1","preferredName":"Oncotype DX Breast Cancer Assay Score","preferredDefinition":"The Oncotype DX score.","longName":"ONCOTPDX_SC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":"0","maxValue":"100","decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2193207","version":"1","preferredName":"Score","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"EACFDBFA-EFD4-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-51EB-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-01-06","modifiedBy":"ALAIS","dateModified":"2007-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"}]},{"publicId":"2716207","version":"1","longName":"ASCO (American Society of Clinical Oncology)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812713","version":"1","longName":"Breast Cancer Adjuvant Treatment","context":"NCIP"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280815","version":"1","longName":"NWU2015-06-04","context":"DCP"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"LAB_ONCODX_RSL_SC","type":"USED_BY","context":"CCTG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Oncotype DX Recurrence Score","type":"Preferred Question Text","description":"Oncotype DX Recurrence Score","url":null,"context":"CTEP"},{"name":"DCP Text 1","type":"Alternate Question Text","description":"Recurrence Score Result","url":null,"context":"DCP"},{"name":"MA39","type":"Alternate Question Text","description":"Oncotype Dx Recurrence Score","url":null,"context":"CCTG"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Oncotype Dx Score","url":null,"context":"Alliance"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"09B2172D-A6A2-3051-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-01-06","modifiedBy":"MORENOC","dateModified":"2019-12-06","changeDescription":"**Laboratory Clean-Up**","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}